Merus NV (MRUS) Expected to Announce Earnings of -$0.89 Per Share
Equities analysts predict that Merus NV (NASDAQ:MRUS) will announce earnings of ($0.89) per share for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Merus’ earnings, with the highest EPS estimate coming in at ($0.81) and the lowest estimate coming in at ($0.96). Merus posted earnings per share of ($1.23) in the same quarter last year, which indicates a positive year over year growth rate of 27.6%. The company is scheduled to announce its next quarterly earnings results on Tuesday, July 10th.
On average, analysts expect that Merus will report full-year earnings of ($3.68) per share for the current fiscal year, with EPS estimates ranging from ($3.76) to ($3.59). For the next fiscal year, analysts forecast that the company will post earnings of ($4.26) per share, with EPS estimates ranging from ($4.54) to ($3.97). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover Merus.
Merus (NASDAQ:MRUS) last posted its quarterly earnings results on Thursday, April 26th. The biotechnology company reported ($0.86) EPS for the quarter. The business had revenue of $4.49 million for the quarter. Merus had a negative return on equity of 91.14% and a negative net margin of 530.70%.
Several hedge funds and other institutional investors have recently modified their holdings of MRUS. Deutsche Bank AG increased its stake in shares of Merus by 146.6% in the fourth quarter. Deutsche Bank AG now owns 9,400 shares of the biotechnology company’s stock worth $182,000 after buying an additional 5,588 shares during the period. Bain Capital Public Equity Management LLC purchased a new position in shares of Merus in the fourth quarter worth $8,297,000. Stanley Laman Group Ltd. purchased a new position in shares of Merus in the first quarter worth $860,000. BVF Inc. IL purchased a new position in shares of Merus in the first quarter worth $44,832,000. Finally, Sofinnova Ventures Inc purchased a new position in shares of Merus in the first quarter worth $36,338,000. 43.31% of the stock is currently owned by institutional investors.
Shares of Merus traded up $0.16, hitting $19.78, during trading hours on Thursday, Marketbeat reports. 22,417 shares of the company’s stock were exchanged, compared to its average volume of 33,729. Merus has a 12-month low of $13.23 and a 12-month high of $21.94. The company has a market capitalization of $432.47 million, a PE ratio of -4.61 and a beta of 0.13.
Merus Company Profile
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.